Blueprint Medicines Corp (NASDAQ:BPMC) Insider Sells $34,868.30 in Stock

Blueprint Medicines Corp (NASDAQ:BPMC) insider Ariel Hurley sold 415 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $84.02, for a total transaction of $34,868.30. Following the transaction, the insider now owns 415 shares in the company, valued at $34,868.30. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Ariel Hurley also recently made the following trade(s):

  • On Friday, July 19th, Ariel Hurley sold 115 shares of Blueprint Medicines stock. The shares were sold at an average price of $100.00, for a total transaction of $11,500.00.
  • On Monday, July 15th, Ariel Hurley sold 830 shares of Blueprint Medicines stock. The shares were sold at an average price of $94.98, for a total transaction of $78,833.40.
  • On Monday, June 17th, Ariel Hurley sold 1,405 shares of Blueprint Medicines stock. The shares were sold at an average price of $98.22, for a total transaction of $137,999.10.
  • On Thursday, June 13th, Ariel Hurley sold 2,733 shares of Blueprint Medicines stock. The shares were sold at an average price of $88.04, for a total transaction of $240,613.32.

Shares of BPMC stock traded down $2.79 on Monday, reaching $81.27. The company had a trading volume of 557,654 shares, compared to its average volume of 461,085. The company has a 50-day moving average of $94.06 and a 200-day moving average of $84.40. Blueprint Medicines Corp has a 12 month low of $44.58 and a 12 month high of $102.98. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 0.16. The stock has a market cap of $4.13 billion, a PE ratio of -15.08 and a beta of 1.55.



Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.92) by ($0.12). Blueprint Medicines had a negative return on equity of 73.73% and a negative net margin of 4,268.74%. The business had revenue of $5.11 million for the quarter, compared to the consensus estimate of $1.39 million. During the same period in the previous year, the company posted ($0.62) earnings per share. Blueprint Medicines’s revenue for the quarter was down 87.7% compared to the same quarter last year. Sell-side analysts anticipate that Blueprint Medicines Corp will post -8.45 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its stake in Blueprint Medicines by 5.3% during the 1st quarter. FMR LLC now owns 6,939,294 shares of the biotechnology company’s stock worth $555,491,000 after purchasing an additional 346,738 shares in the last quarter. Vanguard Group Inc. increased its stake in Blueprint Medicines by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,281,362 shares of the biotechnology company’s stock worth $403,861,000 after purchasing an additional 321,857 shares in the last quarter. BlackRock Inc. increased its stake in Blueprint Medicines by 20.9% during the 2nd quarter. BlackRock Inc. now owns 4,109,222 shares of the biotechnology company’s stock worth $387,621,000 after purchasing an additional 710,147 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Blueprint Medicines by 9.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,681,291 shares of the biotechnology company’s stock worth $347,256,000 after purchasing an additional 305,682 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Blueprint Medicines by 19,169.3% during the 2nd quarter. Invesco Ltd. now owns 1,801,102 shares of the biotechnology company’s stock worth $169,897,000 after purchasing an additional 1,791,755 shares in the last quarter. 97.45% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently commented on BPMC. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Monday, June 17th. Zacks Investment Research cut Blueprint Medicines from a “buy” rating to a “sell” rating and set a $94.00 price target for the company. in a research note on Wednesday, August 7th. Canaccord Genuity upped their price target on Blueprint Medicines from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Robert W. Baird began coverage on Blueprint Medicines in a research note on Thursday, July 18th. They issued an “outperform” rating and a $120.00 price target for the company. Finally, Deutsche Bank began coverage on Blueprint Medicines in a research note on Thursday, July 18th. They issued a “buy” rating and a $110.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Blueprint Medicines currently has an average rating of “Buy” and a consensus price target of $110.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Read More: What is Cost of Goods Sold (COGS)?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.